MacroGenics Inc Reaches New 12-Month High at $32.08 (MGNX)
MacroGenics (NASDAQ:MGNX)’s share price reached a new 52-week high during mid-day trading on Tuesday, ARN reports. The stock traded as high as $32.08 and last traded at $29.95, with a volume of 66,405 shares traded. The stock had previously closed at $29.31.
A number of research firms have recently commented on MGNX. Analysts at Wedbush initiated coverage on shares of MacroGenics in a research note to investors on Tuesday, December 3rd. They set an “outperform” rating and a $70.00 price target on the stock. Separately, analysts at Lazard Capital Markets initiated coverage on shares of MacroGenics in a research note to investors on Monday, November 4th. They set a “buy” rating on the stock. Finally, analysts at Stifel Nicolaus initiated coverage on shares of MacroGenics in a research note to investors on Monday, November 4th. They set a “buy” rating and a $35.00 price target on the stock. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. MacroGenics has an average rating of “Buy” and an average target price of $42.25.
MacroGenics has a 52 week low of $21.50 and a 52 week high of $30.25. The stock’s 50-day moving average is $26.16 and its 200-day moving average is $26.31. The company has a market cap of $788.9 million and a P/E ratio of 75.15.
MacroGenics (NASDAQ:MGNX) last released its earnings data on Tuesday, November 12th. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by $0.14. Analysts expect that MacroGenics will post $-0.73 EPS for the current fiscal year.
MacroGenics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.